ALNYLAM PHARMACEUTICALS INC

NASDAQ: ALNY (Alnylam Pharmaceuticals, Inc.)

Last update: 28 Feb, 8:30AM

332.92

1.68 (0.51%)

  • 1D 0.51%
  • 5D 0.00%
  • 1M 4.04%
  • 6M -26.84%
  • YTD -16.81%
  • 1Y 36.15%
  • 5Y 140.17%
Previous Close 331.24
Open 331.24
Volume 1,379,768
Avg. Volume (3M) 1,556,337
Market Cap 44,152,897,536
Price / Earnings (TTM) 142.88
Price / Earnings (Forward) 35.71
Price / Sales 11.87
Price / Book 55.00
52 Weeks Range
205.87 (-38%) — 495.55 (48%)
Earnings Date 30 Apr 2026
Profit Margin -11.49%
Operating Margin (TTM) 3.04%
Diluted EPS (TTM) -2.11
Quarterly Revenue Growth (YOY) 20.20%
Total Debt/Equity (MRQ) 2,358.25%
Current Ratio (MRQ) 3.04
Operating Cash Flow (TTM) -45.11 M
Levered Free Cash Flow (TTM) 223.09 M
Return on Assets (TTM) -1.79%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Alnylam Pharmaceuticals, Inc. Bearish Bullish

AIStockmoo Score

1.2
Analyst Consensus 2.0
Insider Activity 0.0
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average 1.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ALNY 44 B - 142.88 55.00
ABVX 9 B - - 16.28
TECH 8 B 0.59% 102.32 4.50
REGN 83 B 0.46% 18.83 2.57
ONC 35 B - 621.55 8.49
MLTX 1 B - - 1.34

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Sector Healthcare
Industry Biotechnology
Investment Style Mid Core
% Held by Insiders 3.81%
% Held by Institutions 97.56%
52 Weeks Range
205.87 (-38%) — 495.55 (48%)
Price Target Range
351.00 (5%) — 530.00 (59%)
High 530.00 (Truist Securities, 59.20%) Buy
Median 462.00 (38.77%)
Low 351.00 (Leerink Partners, 5.43%) Hold
Average 454.69 (36.58%)
Total 10 Buy, 3 Hold
Avg. Price @ Call 350.85
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 18 Feb 2026 510.00 (53.19%) Buy 332.68
30 Jan 2026 510.00 (53.19%) Buy 338.06
Canaccord Genuity 17 Feb 2026 429.00 (28.86%) Buy 332.61
Freedom Capital Markets 17 Feb 2026 410.00 (23.15%) Buy 332.61
Chardan Capital 13 Feb 2026 425.00 (27.66%) Buy 314.40
Needham 12 Feb 2026 510.00 (53.19%) Buy 308.48
12 Jan 2026 529.00 (58.90%) Buy 370.91
B of A Securities 30 Jan 2026 462.00 (38.77%) Buy 338.06
12 Jan 2026 529.00 (58.90%) Buy 370.91
Morgan Stanley 30 Jan 2026 408.00 (22.55%) Hold 338.06
Barclays 28 Jan 2026 527.00 (58.30%) Buy 349.58
RBC Capital 20 Jan 2026 465.00 (39.67%) Buy 355.53
Wells Fargo 20 Jan 2026 376.00 (12.94%) Hold 355.53
Truist Securities 08 Jan 2026 530.00 (59.20%) Buy 399.40
Leerink Partners 15 Dec 2025 351.00 (5.43%) Hold 391.50
Stifel 11 Dec 2025 508.00 (52.59%) Buy 412.63
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
FITZGERALD KEVIN JOSEPH 327.21 321.86 596 205,024
GARG PUSHKAL 325.07 325.55 -3,350 -1,113,911
GREENSTREET YVONNE 325.07 325.07 7,045 2,290,118
POULTON JEFFREY V. 325.07 325.07 2,563 833,154
SUPRAN BRYAN 325.07 - 1,539 500,283
TANGULER TOLGA 325.07 325.07 3,171 1,030,797
Aggregate Net Quantity 11,564
Aggregate Net Value ($) 3,745,465
Aggregate Avg. Buy ($) 325.68
Aggregate Avg. Sell ($) 324.45
Insider Range ($)
325.07 (-2%) — 332.92 (0%)
Name Holder Date Type Quantity Price Value ($)
FITZGERALD KEVIN JOSEPH Officer 03 Mar 2026 Automatic sell (-) 1,652 318.65 526,410
GARG PUSHKAL Officer 03 Mar 2026 Automatic sell (-) 1,775 318.65 565,604
GREENSTREET YVONNE Officer 02 Mar 2026 Acquired (+) 13,844 325.07 4,500,269
GREENSTREET YVONNE Officer 02 Mar 2026 Sell (-) 6,799 325.07 2,210,151
SUPRAN BRYAN Officer 02 Mar 2026 Acquired (+) 1,539 325.07 500,283
TANGULER TOLGA Officer 02 Mar 2026 Acquired (+) 4,769 325.07 1,550,259
TANGULER TOLGA Officer 02 Mar 2026 Sell (-) 1,598 325.07 519,462
FITZGERALD KEVIN JOSEPH Officer 02 Mar 2026 Acquired (+) 3,688 325.07 1,198,858
FITZGERALD KEVIN JOSEPH Officer 02 Mar 2026 Sell (-) 1,598 325.07 519,462
GARG PUSHKAL Officer 02 Mar 2026 Acquired (+) 4,769 325.07 1,550,259
GARG PUSHKAL Officer 02 Mar 2026 Sell (-) 1,717 325.07 558,145
POULTON JEFFREY V. Officer 02 Mar 2026 Acquired (+) 4,769 325.07 1,550,259
POULTON JEFFREY V. Officer 02 Mar 2026 Sell (-) 2,206 325.07 717,104
GARG PUSHKAL Officer 27 Feb 2026 Automatic sell (-) 4,627 332.92 1,540,421
GARG PUSHKAL Officer 27 Feb 2026 Option execute 1,908 - -
TANGULER TOLGA Officer 27 Feb 2026 Option execute 1,666 - -
POULTON JEFFREY V. Officer 27 Feb 2026 Option execute 1,908 - -
GREENSTREET YVONNE Officer 27 Feb 2026 Option execute 5,921 - -
FITZGERALD KEVIN JOSEPH Officer 23 Feb 2026 Acquired (+) 158 329.35 52,037
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria